Rubicon Research IPO Day 2: Track GMP, subscription status, broker insights and key highlights

Rubicon Research’s Rs 1,377 crore IPO, which opened for subscription on October 9, has now entered its second day. The issue was 51% subscribed, with bids for 84.62 lakh shares against the 1.64 crore shares offered by the end of Day 1.

Market observers report that Rubicon Research is trading at a gray market premium (GMP) of Rs 85, about 17.5% above the high end, indicating strong expectations for the listing, driven by investor interest in the healthcare and pharmaceutical sectors.

Rubicon Research, a pharmaceutical manufacturer specializing in specialty and generic drugs, has set its price range between Rs 461 and Rs 485 per share, valuing the company at around Rs 7,990 crore. The IPO consists of a fresh issue of Rs 500 crore and an offer for sale (OFS) worth Rs 877 crore.

Rubicon Research IPO Subscription Status

At the end of Day 1 bidding, the Rubicon Research IPO was 51% subscribed in total, indicating muted investor interest on the first day.

Among different investor categories, Retail Individual Investors (RIIs) showed great enthusiasm and subscribed 1.36 times for the 29.84 lakh shares allotted to them, reflecting healthy demand from individual investors.

Non-institutional investors (NIIs), including high net worth individuals and others, have subscribed to 47% of their reserved quota of 44.76 lakh shares, indicating a more cautious approach from this group.

Qualified Institutional Buyers (QIBs), usually large institutional investors, bid for 26% of their allocation of 89.52 lakh shares, indicating relatively lower participation from institutions on the first day.

Rubicon Research GMP

According to market experts, Rubicon Research is trading at a gray market premium (GMP) of Rs 85, around 17.5% higher than the IPO’s highest price range. This indicates robust investor confidence and optimistic expectations for a strong stock market listing, mainly fueled by interest in the healthcare and pharmaceutical sectors.

Broker rating

Arihant Capital has assigned a ‘Subscribe’ rating to Rubicon Research’s IPO, highlighting the company’s strong growth prospects and well-diversified product portfolio.

According to the brokerage’s IPO report, “Rubicon Research is a fully integrated pharmaceutical development company with a notable presence in the U.S. generic and specialty markets. Its leadership in the U.S. generic segment, along with its strategic expansion into specialty pharmaceuticals through the acquisition of Validus, positions the company for sustainable long-term growth.”

The IPO is considered reasonably valued and trades at a price-to-earnings ratio of approximately 60 times estimated FY25 earnings, while offering scalability and clear visibility in international markets.

Company overview

Rubicon Research operates in the US, Canada and India and offers differentiated formulations in both generic and specialty medicines. As of June 2025, the company has 72 US FDA-approved products, with 17 pending approval and another 63 in the pipeline. It operates three manufacturing facilities in India and has two R&D centers in India and Canada.

The acquisition of Validus Pharmaceuticals in the US represents a strategic move toward specialty branded medicines, giving Rubicon direct access to prescribers in 44 states.

Financial data

Rubicon has shown significant financial turnaround. Revenue rose to Rs 12,962 crore in FY25 from Rs 4,190 crore in FY23, while net profit rose to Rs 1,344 crore, recovering from a loss of Rs 169 crore two years earlier. EBITDA margins also improved substantially, from 10% in FY23 to 21% in FY25, due to greater operational efficiencies.

Also read: Groww to launch a Rs 7,000 crore IPO in November

Analysts believe the IPO is likely to attract both institutional and retail investors interested in a fast-growing mid-market pharmaceutical exporter. With its improving profitability, growing global presence and strategic entry into the US market, Rubicon is well positioned for long-term sustainable value creation.

The IPO will be listed on both the NSE and BSE, with Axis Capital acting as lead manager and MUFG Intime India as registrar.

(Disclaimer: Recommendations, suggestions, views and opinions expressed by the experts are their own. These do not represent the views of the Economic Times)